JP2001501612A - 虚血性疾患を治療する方法及び発作後の症状を改善する方法 - Google Patents

虚血性疾患を治療する方法及び発作後の症状を改善する方法

Info

Publication number
JP2001501612A
JP2001501612A JP10515905A JP51590598A JP2001501612A JP 2001501612 A JP2001501612 A JP 2001501612A JP 10515905 A JP10515905 A JP 10515905A JP 51590598 A JP51590598 A JP 51590598A JP 2001501612 A JP2001501612 A JP 2001501612A
Authority
JP
Japan
Prior art keywords
selectin
cerebral
surgery
mice
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10515905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001501612A5 (enExample
Inventor
ピンスキー、デビット・ジェイ
スタン、デビット
シュミット、アン・マリー
ローズ、エリック・エー
コノリー、イー・サンダー
ソロモン、ロバート・エー
プレスチジャコモ、チャールズ・ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2001501612A publication Critical patent/JP2001501612A/ja
Publication of JP2001501612A5 publication Critical patent/JP2001501612A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
JP10515905A 1996-09-27 1997-09-25 虚血性疾患を治療する方法及び発作後の症状を改善する方法 Pending JP2001501612A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72144796A 1996-09-27 1996-09-27
US08/721,447 1996-09-27
PCT/US1997/017229 WO1998013058A1 (en) 1996-09-27 1997-09-25 Methods for treating an ischemic disorder and improving stroke outcome

Publications (2)

Publication Number Publication Date
JP2001501612A true JP2001501612A (ja) 2001-02-06
JP2001501612A5 JP2001501612A5 (enExample) 2005-05-12

Family

ID=24898028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10515905A Pending JP2001501612A (ja) 1996-09-27 1997-09-25 虚血性疾患を治療する方法及び発作後の症状を改善する方法

Country Status (10)

Country Link
EP (2) EP1829550A3 (enExample)
JP (1) JP2001501612A (enExample)
AT (1) ATE358492T1 (enExample)
AU (1) AU4594297A (enExample)
CA (1) CA2266640C (enExample)
DE (1) DE69737562T2 (enExample)
DK (1) DK0951292T3 (enExample)
ES (1) ES2285740T3 (enExample)
PT (1) PT951292E (enExample)
WO (1) WO1998013058A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500875A (ja) * 2001-06-21 2005-01-13 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素
JP2005525848A (ja) * 2002-02-13 2005-09-02 ベス イスラエル ディコネス メディカル センター 血管疾患の治療方法
JP2005531534A (ja) * 2002-04-15 2005-10-20 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
JP2009167223A (ja) * 2001-11-13 2009-07-30 Univ Duke 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用
JP2009215311A (ja) * 2001-05-15 2009-09-24 Hemocorm Ltd 一酸化炭素の治療目的での放出
WO2013162078A1 (ja) * 2012-04-27 2013-10-31 学校法人日本大学 上皮及び内皮損傷の治療剤
JP2017052788A (ja) * 2008-11-11 2017-03-16 バンワールド ファーマシューティカル（ルガオ） カンパニー リミテッド ワクシニアウイルスによって炎症を起こしたウサギ皮膚由来の抽出物の、急性脳血管疾患の治療用医薬の製造における使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712226A3 (en) * 1996-04-05 2007-03-21 The General Hospital Corporation Treatment of a Hemoglobinopathy
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE355029T1 (de) * 1998-04-01 2006-03-15 Univ Columbia Verfahren zur thrombosehemmung bei patienten deren blut extrakorporaler zirkulation ausgesetzt ist
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US20030198639A1 (en) * 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
AU2003223562B2 (en) * 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
AU2003226366A1 (en) 2002-04-15 2003-11-03 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
CN1719975A (zh) * 2002-11-07 2006-01-11 联邦高等教育系统匹兹堡大学 出血性休克的治疗
WO2005041656A2 (en) * 2003-10-22 2005-05-12 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
LT2264043T (lt) 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2010054393A1 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2022011247A1 (en) * 2020-07-10 2022-01-13 Children's Medical Center Corporation Targeted drug delivery to sites of intravascular occlusion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020400A1 (en) * 1994-01-28 1995-08-03 Japan Tobacco Inc. Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
WO1995021180A1 (en) * 1994-02-01 1995-08-10 Glycomed Incorporated Substituted lactose derivatives as cell adhesion inhibitors
JPH08502242A (ja) * 1992-05-22 1996-03-12 ザ リサーチ アンド ディベラップメント インスチチュート，インコーポレイテッド 多重付着分子に対する特異性を有する抗体
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
DE4403057C1 (de) * 1994-02-02 1994-12-08 Biotest Pharma Gmbh Thrombozytenstabilisierende Faktor IX-Fragmente, deren Herstellung sowie sie enthaltende Arzneimittel
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502242A (ja) * 1992-05-22 1996-03-12 ザ リサーチ アンド ディベラップメント インスチチュート，インコーポレイテッド 多重付着分子に対する特異性を有する抗体
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
WO1995020400A1 (en) * 1994-01-28 1995-08-03 Japan Tobacco Inc. Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
WO1995021180A1 (en) * 1994-02-01 1995-08-10 Glycomed Incorporated Substituted lactose derivatives as cell adhesion inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009215311A (ja) * 2001-05-15 2009-09-24 Hemocorm Ltd 一酸化炭素の治療目的での放出
JP2005500875A (ja) * 2001-06-21 2005-01-13 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素
JP2009167223A (ja) * 2001-11-13 2009-07-30 Univ Duke 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用
JP2005525848A (ja) * 2002-02-13 2005-09-02 ベス イスラエル ディコネス メディカル センター 血管疾患の治療方法
JP2005531534A (ja) * 2002-04-15 2005-10-20 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
JP2017052788A (ja) * 2008-11-11 2017-03-16 バンワールド ファーマシューティカル（ルガオ） カンパニー リミテッド ワクシニアウイルスによって炎症を起こしたウサギ皮膚由来の抽出物の、急性脳血管疾患の治療用医薬の製造における使用
WO2013162078A1 (ja) * 2012-04-27 2013-10-31 学校法人日本大学 上皮及び内皮損傷の治療剤
US9738884B2 (en) 2012-04-27 2017-08-22 Nihon University Therapeutic agent for epithelial and endothelial injury

Also Published As

Publication number Publication date
WO1998013058A1 (en) 1998-04-02
EP1829550A3 (en) 2008-04-30
EP0951292B1 (en) 2007-04-04
EP0951292A1 (en) 1999-10-27
DE69737562D1 (de) 2007-05-16
ES2285740T3 (es) 2007-11-16
PT951292E (pt) 2007-06-18
DE69737562T2 (de) 2007-12-27
EP1829550A2 (en) 2007-09-05
AU4594297A (en) 1998-04-17
ATE358492T1 (de) 2007-04-15
CA2266640C (en) 2011-05-24
DK0951292T3 (da) 2007-08-13
CA2266640A1 (en) 1998-04-02
EP0951292A4 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
JP2001501612A (ja) 虚血性疾患を治療する方法及び発作後の症状を改善する方法
US6316403B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) Methods for treating ischemic disorders using carbon monoxide
Flügel et al. Species differences in choroidal vasodilative innervation: evidence for specific intrinsic nitrergic and VIP-positive neurons in the human eye.
WO1998013058A9 (en) Methods for treating an ischemic disorder and improving stroke outcome
US5847007A (en) Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Choudhri et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
Dworkin et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms
JPH03505329A (ja) 心筋梗塞の処置のための方法および治療用組成物
Grover et al. Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
JP5400006B2 (ja) 虚血性疾患の予防または治療剤
JP4212114B2 (ja) 抗血栓剤としてのｐ１，ｐ４―ジチオ―ｐ２―ｐ３―モノクロロメチレン５’，５’’’―ジアデノシン ｐ１，ｐ４―テトラホスフェート
US6867177B2 (en) CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
JP2012530735A (ja) 眼疾患の治療におけるＣＤ４４ｖ６の使用
JP6797826B2 (ja) 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体
BR112020015561A2 (pt) Proteínas anticoagulantes e seus usos para tratar doenças associadas à ativação de neutrófilos
US8563511B2 (en) Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
Gong et al. Effects of aging on autophagy after experimental intracerebral hemorrhage
WO2018137701A1 (zh) 靶向cxcr7的药物组合物和方法
MXPA99002996A (en) Methods for treating an ischemic disorder and improving stroke outcome
Wurtzel et al. Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice
US20240108591A1 (en) Or2l13 agonists to treat cvd with dysregulated platelet activation
JP2001524534A (ja) 播種性血管内凝固を予防するためのフィブリノーゲン受容体アンタゴニストの使用
Benemei et al. Migraine models
GB2374870A (en) Use of genetically modified multicellular animals in the identification of drug target proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116